Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Statement re Offer for Subscription

8 Apr 2020 15:56

RNS Number : 2648J
Maven Income and Growth VCT 3 PLC
08 April 2020
 

Joint Announcement

Maven Income and Growth VCT 3 PLC and Maven Income and Growth VCT 4 PLC (the "Companies")

Issue of Supplementary Prospectus

The Boards of the Companies today announce that they have published a supplementary prospectus (the "Supplementary Prospectus") relating to the Top-up Offers issued by the Companies, details of which were set out in their prospectus issued on 13 November 2019 (the "Offers").

The publication of the Supplementary Prospectus is a regulatory requirement under the Prospectus Regulation Rules and Section 87G of Financial Services and Market Act 2000 following (i) the publication by Maven Income and Growth VCT 3 PLC on 10 March 2020 of the annual financial results for the year ended 30 November 2019 and (ii) the publication by each of the Companies on 26 March 2020 of an unaudited net asset value per share as at 20 March 2020 reflecting a review of their respective portfolios carried out in response to the changing market conditions arising from the Coronavirus (Covid-19) pandemic.

 

The Supplementary Prospectus has been approved by the Financial Conduct Authority, and copies will shortly be available for inspection at the National Storage Mechanism, which is located at: https://www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism, and are available free of charge from the office of the investment manager of the Companies, Maven Capital Partners UK LLP, at Kintyre House, 205 West George Street, Glasgow G2 2LW and from the website of Maven Capital Partners UK LLP at: www.mavencp.com/vctoffer.

The Offers are now fully subscribed and are closed to further applications.

Enquiries

For further information, please contact:

Maven Capital Partners UK LLP

Tel: 0141 306 7400

E-mail: enquiries@mavencp.com

Maven Capital Partners UK LLP

Secretary

8 April 2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRZVLFBBZLEBBX
Date   Source Headline
20th May 202610:12 amRNSAdmission of Further Securities to Trading
15th May 202610:45 amRNSDirector/PDMR Shareholding
15th May 202610:41 amRNSIssue of Equity - Dividend Investment Scheme
14th May 20265:22 pmRNSTransaction in Own Shares
12th May 20263:37 pmRNSUnaudited NAV - Dividend Investment Scheme
7th May 20261:45 pmRNSResult of AGM
30th Apr 202610:58 amRNSAdmission of Further Securities to Trading
29th Apr 202612:29 pmRNSIssue of Equity
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:27 amRNSAdmission of Further Securities to Trading
14th Apr 202611:09 amRNSIssue of Equity
10th Apr 202612:02 pmRNSUnaudited Net Asset Value
8th Apr 20269:33 amRNSAdmission of Further Securities to Trading
25th Mar 20263:51 pmRNSTransaction in Own Shares
25th Mar 202610:55 amRNSAdmission of Further Securities to Trading
24th Mar 202612:11 pmRNSIssue of Equity
19th Mar 20264:21 pmRNSUnaudited NAV and Proposed Final Dividend
18th Feb 20264:58 pmRNSAdmission of Further Securities to Trading
17th Feb 202611:07 amRNSDirector/PDMR Shareholding
17th Feb 202611:07 amRNSDirector/PDMR Shareholding
17th Feb 202610:54 amRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
21st Jan 202611:07 amRNSAdmission of Further Securities to Trading
20th Jan 20262:05 pmRNSAdmission of Further Securities to Trading
16th Jan 20269:52 amRNSDirector/PDMR Shareholding
16th Jan 20269:44 amRNSIssue of Equity
15th Jan 202610:36 amRNSDirector/PDMR Shareholding
15th Jan 202610:35 amRNSDirector/PDMR Shareholding
15th Jan 20269:55 amRNSIssue of Equity
14th Jan 20262:39 pmRNSUnaudited NAV - Dividend Investment Scheme
13th Jan 202612:10 pmRNSUnaudited Net Asset Value
4th Dec 202510:35 amRNSSecond Interim Dividend
18th Nov 20253:48 pmRNSTransaction in Own Shares
14th Nov 20259:31 amRNSNet Asset Value(s)
13th Nov 20254:53 pmRNSResult of General Meeting
2nd Oct 20254:42 pmRNSPublication of a Prospectus
29th Aug 20257:00 amRNSDirector/PDMR Shareholding
29th Aug 20257:00 amRNSIssue of Equity
29th Aug 20257:00 amRNSHalf-year Report
20th Aug 20252:14 pmRNSStatement re Dividend Investment Scheme
31st Jul 20254:42 pmRNSTransaction in Own Shares
16th Jul 202510:18 amRNSStatement re Unaudited NAV and Interim Dividend
16th Jul 20257:08 amRNSStatement re Offer for Subscription
21st May 20254:44 pmRNSTransaction in Own Shares
16th May 20259:30 amRNSDirector/PDMR Shareholding
16th May 20259:26 amRNSIssue of Equity - Dividend Investment Scheme
9th May 20251:53 pmRNSStatement re Dividend Investment Scheme
9th May 202510:03 amRNSNet Asset Value(s)
8th May 20251:43 pmRNSResult of AGM
6th May 202511:55 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.